Valerius T - Search Results

1

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.

Evers M, Rösner T, Dünkel A, Jansen JHM, Baumann N, Ten Broeke T, Nederend M, Eichholz K, Klausz K, Reiding K, Schewe DM, Kellner C, Peipp M, Leusen JHW, Valerius T. Evers M, et al. Among authors: valerius t. Blood Adv. 2021 Oct 12;5(19):3807-3820. doi: 10.1182/bloodadvances.2021004598. Blood Adv. 2021. PMID: 34525171 Free PMC article.

2

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Repp R, et al. Among authors: valerius t. Blood. 1991 Aug 15;78(4):885-9. Blood. 1991. PMID: 1714327 Free article.

3

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1993 Aug 1;82(3):931-9. Blood. 1993. PMID: 7687898 Free article.

4

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

5

IgA antibodies for cancer therapy.

Dechant M, Valerius T. Dechant M, et al. Among authors: valerius t. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):69-77. doi: 10.1016/s1040-8428(01)00105-6. Crit Rev Oncol Hematol. 2001. PMID: 11418303 Review.

6

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T. Peipp M, et al. Among authors: valerius t. Biochem Soc Trans. 2002 Aug;30(4):507-11. doi: 10.1042/bst0300507. Biochem Soc Trans. 2002. PMID: 12196124 Review.

7

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van De Winkel JG, Valerius T. Dechant M, et al. Among authors: valerius t. Blood. 2002 Dec 15;100(13):4574-80. doi: 10.1182/blood-2002-03-0687. Epub 2002 Aug 8. Blood. 2002. PMID: 12393717 Free article.

8

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Teeling JL, et al. Among authors: valerius t. Blood. 2004 Sep 15;104(6):1793-800. doi: 10.1182/blood-2004-01-0039. Epub 2004 Jun 1. Blood. 2004. PMID: 15172969 Free article.

9

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH. Bruenke J, et al. Among authors: valerius t. Br J Haematol. 2005 Jul;130(2):218-28. doi: 10.1111/j.1365-2141.2005.05414.x. Br J Haematol. 2005. PMID: 16029450 Free article.

10

Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.

Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T. Dechant M, et al. Among authors: valerius t. J Immunol. 2007 Sep 1;179(5):2936-43. doi: 10.4049/jimmunol.179.5.2936. J Immunol. 2007. PMID: 17709508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176 results

Search Page